Inbound Relationships |
Type |
Active |
Source |
Characteristic |
Refinability |
Group |
Anterior pituitary hormone |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatomedin |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Antidiuretic hormone |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Panhypopituitarism - anterior and posterior |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
X-linked panhypopituitarism (disorder) |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Prepuberal panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Pituitary dwarfism with small sella turcica |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Idiopathic panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Post-birth injury panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Post-infarction panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Other specified panhypopituitarism |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Panhypopituitarism NOS |
Interprets |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Hormone radioassay - pituitary |
Component |
True |
Pituitary hormone |
Inferred relationship |
Some |
1 |
Corticotropin preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing melatonin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Human growth hormone recombinant preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Hormone-induced hypopituitarism |
Causative agent (attribute) |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Corticotrophins |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Posterior pituitary hormones |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Pituitary (posterior lobe) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatrophic hormone |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing anterior pituitary hormone (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin (substance) |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing somatotropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing pituitary hormone (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
True |
Pituitary hormone |
Inferred relationship |
Some |
1 |
Pituitary luteinizing hormone |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Anterior pituitary extract preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing corticotropin releasing factor (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Posterior pituitary hormone |
Is a |
True |
Pituitary hormone |
Inferred relationship |
Some |
|
Macroprolactin (substance) |
Is a |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing follitropin alfa (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing follitropin beta (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing sermorelin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Sermorelin acetate |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Corticotropin preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing melatonin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Corticotrophins |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone alpha 75iu powder and solvent for injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone alpha 150iu powder and solvent for injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone beta 600iu/0.72mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone beta 300iu/0.36mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone alpha 37.5iu powder and solvent for injection solution ampule |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone beta 100iu/mL injection solution 0.5ml vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
hormone folliculostimulante humaine recombinante bêta 200 UI/mL, fiole de 0,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
hormone folliculostimulante humaine recombinante bêta 300 UI/mL, fiole de 0,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Recombinant human follicle stimulating hormone beta 400iu/mL injection solution 0.5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing tetracosactide (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
cosyntrophine 250 microgrammes/1mL pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
cosyntrophine 1 mg/1mL pour injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 1,8 UI (0,6 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 1,2 UI (0,4 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 0,6 UI (0,2 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (rmc) 24 UI (8 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 16 UI (5,33 mg), poudre et diluant pour injection avec nécessaire de reconstitution |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 12 UI (4 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 2,4 UI (0,8 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 3 UI (1 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 16 UI (5,33 mg), cartouche de poudre pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 16 UI (5,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (rmc) 10 UI (3,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (rmc) 4 UI (1,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 4 UI (1,33 mg), fiole de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin 12 mg powder for solution for injection cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 18 UI (6 mg), cartouche de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 36 UI (12 mg), cartouche de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 72 UI (24 mg), cartouche de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
sermoréline 50 microgrammes, ampoules de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 3,6 UI (1,2 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 4,2 UI (1,4 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 4,8 UI (1,6 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 5,4 UI (1,8 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (efficacité biologique relative) 6 UI (2 mg), seringue préremplie de poudre et solvant pour solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (epr) 3,33 mg/mL, cartouche de 1,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (epr) 6,66 mg/mL, cartouche de 1,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
somatropine (epr) 10 mg/mL, cartouche de 1,5 mL de solution injectable |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin 4mg/vial powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin 8.8mg/vial powder for injection |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin 13.5mg/3mL injection solution 3mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin 18mg/3mL injection solution 3mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin 22.5mg/3mL injection solution 3mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatrophic hormone |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Somatropin(rbe) 5mg(15iu)/mL injection solution 2mL cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Follitropin alfa 300iu injection solution 0.5mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Follitropin alfa 450iu injection solution 0.75mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Follitropin alfa 900iu injection solution 1.5mL prefilled pen |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Cosyntropin 25mcg/mannitol 10mg injection solution vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing somatrem (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing pituitary gonadotropin (product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Cosyntropin preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Human growth hormone recombinant preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Bovine growth hormone recombinant preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Sometribove preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing human menopausal gonadotropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing somatotropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing corticotropin zinc hydroxide |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Anterior pituitary extract preparation |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing prolactin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Corticotropin 80units/mL in gelatin injection solution 5mL vial |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Product containing somatropin (medicinal product) |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|
Follitropin beta 300iu injection solution cartridge |
The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications. |
False |
Pituitary hormone |
Inferred relationship |
Some |
|